News | December 09, 2024
Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
New research labs and process development services to enable next generation therapeutics
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
